Biocytogen Pharmaceuticals (Beijing) Balance Sheet Health
Financial Health criteria checks 4/6
Biocytogen Pharmaceuticals (Beijing) has a total shareholder equity of CN¥744.2M and total debt of CN¥395.5M, which brings its debt-to-equity ratio to 53.1%. Its total assets and total liabilities are CN¥2.4B and CN¥1.7B respectively.
Key information
53.1%
Debt to equity ratio
CN¥395.48m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥424.07m |
| Equity | CN¥744.24m |
| Total liabilities | CN¥1.69b |
| Total assets | CN¥2.43b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: I54's short term assets (CN¥766.1M) exceed its short term liabilities (CN¥572.6M).
Long Term Liabilities: I54's short term assets (CN¥766.1M) do not cover its long term liabilities (CN¥1.1B).
Debt to Equity History and Analysis
Debt Level: I54 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if I54's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: I54 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: I54 has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 35.5% each year.